Insider · SEC Form 4 filer
RA Capital Nexus Fund III, L.P.
Companies
Where they file as an insider
Artiva Biotherapeutics (ARTV) Director Latest filing Jul 24, 2026
Parabilis Medicines (PBLS) Director Latest filing Jun 11, 2026
Sionna Therapeutics (SION) Director Latest filing Oct 28, 2025
Mineralys Therapeutics (MLYS) Director Latest filing Mar 13, 2025
Bicara Therapeutics (BCAX) Director Latest filing Sep 16, 2024
Track record
Did their buys beat the typical stock?
Open-market buys7
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check3
Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.
Artiva Biotherapeutics (ARTV) Bought Jul 24, 2026 · $413K · 41,319 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Parabilis Medicines (PBLS) Bought Jun 11, 2026 · $424M · 21.19M shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Artiva Biotherapeutics (ARTV) Bought May 11, 2026 · $75M · 6.51M shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Mineralys Therapeutics (MLYS) Bought Mar 13, 2025 · $17.5M · 1.3M shares Beat typical Mar 31, 2025 $15.88 → Sep 30, 2025 $37.92 · +138.8% (typical stock +7.3%)
Bicara Therapeutics (BCAX) Bought Sep 16, 2024 · $33M · 1.83M shares Behind typical Sep 30, 2024 $25.47 → Mar 31, 2025 $13.03 · −48.8% (typical stock −7.5%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.